News As Streeting threatens no deal, talks on drug levy collapse The UK government's threat to withdraw from negotiations on rebates paid by industry on NHS medicines has been followed by the collapse of talks.
News New medicines review process under NHS 10-Year Plan emerges More details have emerged of a UK plan for new medicines to get simultaneous decisions from the MHRA and NICE on their use by the NHS.
News UK plan to lead life sciences gets mixed response The UK has unveiled its plan to revitalise the life sciences sector and become a global leader by 2030, but a pharma trade group says it falls short.
News UK pharma has concerns about the new NHS 10-year plan The ABPI is worried about investment in medicines and moves that could limit patient and doctor treatment choice in the NHS 10-year plan.
News UK follows through on doubling of statutory scheme rate UK pharma firms have reacted angrily to the news that the government has doubled the statutory scheme rebate on the sales of newer drugs to the NHS.
Market Access Buyer’s remorse: The UK’s VPAG With the ABPI wanting to change the scheme just over a year into its five-year term, it seems that they have buyer’s remorse.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.